New combo therapy aims to stop returning brain tumors
NCT ID NCT04659811
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether combining stereotactic radiosurgery (precise, high-dose radiation) with the immunotherapy drug pembrolizumab (Keytruda) can help control recurrent meningioma, a type of brain tumor. The study enrolls 35 adults whose tumors have returned after prior surgery and radiation. The main goal is to see how many patients remain progression-free after 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda) and stereotactic radiosurgery
What this could lead to
If successful, this combination could offer a new treatment option that delays tumor regrowth in patients with recurrent meningioma.
What could go wrong
This is a small, early-phase study (35 participants) without a control group, so results may not confirm benefit. Pembrolizumab can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States